These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25897765)

  • 1. The Middle East-North Africa region: a cocoon for clinical trials.
    Al Tajir G; Al-Rawi Y
    Account Res; 2015; 22(4):201-4. PubMed ID: 25897765
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials in the Middle East and North Africa (MENA) Region: grandstanding or grandeur?
    Nair SC; Ibrahim H; Celentano DD
    Contemp Clin Trials; 2013 Nov; 36(2):704-10. PubMed ID: 23712082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [No one is expected to ignore... the legal status of drug promotional studies].
    Cereghetti A
    Rev Med Suisse; 2006 Oct; 2(82):2307-10. PubMed ID: 17124859
    [No Abstract]   [Full Text] [Related]  

  • 4. Strategic imperatives for globalization of industries in developing countries: an Indian pharmaceutical industry example.
    Srivastava R; Chandra A; Kumar G
    Health Mark Q; 2004; 22(1):57-69. PubMed ID: 15914384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bio-Vision 2016: the second national framework plan for biotechnology promotion in Korea.
    Hyeon BH; Kim HY; Lee CM; Moon SH; Kim ES; Lee SY
    Biotechnol J; 2008 May; 3(5):591-600. PubMed ID: 18446865
    [No Abstract]   [Full Text] [Related]  

  • 6. MEP calls for tougher legislation to stop drug trials that could be considered as marketing.
    Cohen D
    BMJ; 2012 Jun; 344():e4247. PubMed ID: 22718958
    [No Abstract]   [Full Text] [Related]  

  • 7. Research governance--global or local?
    Mansell MA
    Med Leg J; 2001; 69(Pt 1):1-3. PubMed ID: 11388065
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials in "emerging markets": regulatory considerations and other factors.
    Singh R; Wang O
    Contemp Clin Trials; 2013 Nov; 36(2):711-8. PubMed ID: 24070788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia.
    Kudrin A
    J Clin Pharmacol; 2009 Mar; 49(3):268-80. PubMed ID: 19168433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investment managers back greater transparency of clinical trials.
    Hawkes N
    BMJ; 2015 Jul; 351():h4002. PubMed ID: 26207007
    [No Abstract]   [Full Text] [Related]  

  • 11. The House of Commons Health Committee: 'The Influence of the Pharmaceutical Industry'. Too much too late?
    Kerwin R
    J Psychopharmacol; 2007 Mar; 21(2):131-3. PubMed ID: 17329287
    [No Abstract]   [Full Text] [Related]  

  • 12. Global "hold-em".
    Cassidy BS
    Geriatr Nurs; 2006; 27(1):21-3. PubMed ID: 16483897
    [No Abstract]   [Full Text] [Related]  

  • 13. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug studies in developing countries.
    Olliaro PL; Vijayan R; Inbasegaran K; Lang CC; Looareesuwan S
    Bull World Health Organ; 2001; 79(9):894-5. PubMed ID: 11584742
    [No Abstract]   [Full Text] [Related]  

  • 15. Big pharma under the spotlight.
    Farham B
    S Afr Med J; 2013 May; 103(6):352. PubMed ID: 23725968
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
    Asano K; Tanaka A; Sato T; Uyama Y
    Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary of Demographic and Health Surveys as of October 1993.
    Macro International. Demographic and Health Surveys DHS
    Newsl Macro Syst Inst Resour Dev Demogr Health Surv; 1993; 6(1):6-7. PubMed ID: 12287325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pfizer in "unethical" trial suit.
    Ready T
    Nat Med; 2001 Oct; 7(10):1077. PubMed ID: 11590414
    [No Abstract]   [Full Text] [Related]  

  • 19. Marketing groups merge. Rx communications pros get national organization.
    Robeznieks A
    Mod Healthc; 2007 Jun; 37(25):17. PubMed ID: 17824503
    [No Abstract]   [Full Text] [Related]  

  • 20. Andrew Witty: the acceptable face of big pharma? Interviewed by Rebecca Coombes.
    Witty A
    BMJ; 2013 Mar; 346():f1458. PubMed ID: 23468295
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.